This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Stanford, B. J. Articles by Stanford, S. C. Search for Related Content PubMed PubMed Citation Articles by Stanford, B. J. Articles by Stanford, S. C. Social Bookmarking                         What's this?

Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine?

Department of Anaesthetics, St George's Hospital, Blackshaw Road, London

S. C. Stanford

Department of Pharmacology, University College London, Gower Street, London WC1E 6BT, UK c.stanford{at}ucl.ac.uk

We report a postoperative delirium expressed by a 49-year-old female patient during recovery from anaesthesia. Prominent features of the delirium, which lasted for nearly 2 days, included agitation, confusion, uncontrolled limb movements, abnormal ocular function, hypertension, pyrexia, brisk reflexes, ankle clonus and raised creatine kinase. The delirium did not respond to naloxone, diazepam or flumazenil. The patient had not been prescribed neuroleptics but, before surgery, she had been taking the selective serotonin reuptake inhibitor, paroxetine, to relieve her depression. During surgery, she was given morphine, which increases release of the neurotransmitter, serotonin, and ondansetron, which blunts neuronal release of dopamine. Although there is no clear explanation for the delirium, it had many features in common with problems associated with paroxetine withdrawal, the serotonin syndrome and the malignant neuroleptic syndrome. We offer several alternative explanations for this event, all of which rest on disruption of serotonergic and/or dopaminergic transmission and which could also involve inhibition by paroxetine of the P450 enzyme, CYP2D6, which metabolizes ondansetron.

Key Words: morphine • neuroleptic malignant syndrome • ondansetron • paroxetine • paroxetine withdrawal • postoperative delirium • serotonin syndrome

Journal of Psychopharmacology, Vol. 13, No. 3, 313-317 (1999)
DOI: 10.1177/026988119901300322


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. H. Preskorn Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future J Psychopharmacol, July 1, 2006; 20(4_suppl): 85 - 94. [Abstract] [PDF]

				C. Siebert, S. Kroeber, and N. Lutter Prolonged Postoperative Disorientation After Methylene Blue Infusion During Parathyroidectomy Anesth. Analg., August 1, 2005; 101(2): 608 - 609. [Full Text] [PDF]

				S. M. Sorscher Probable serotonin syndrome variant in a patient receiving a selective serotonin reuptake inhibitor and a 5-HT3 receptor antagonist J Psychopharmacol, March 1, 2002; 16(2): 191 - 191. [PDF]

				S. C. Stanford and B. J. Stanford Reply to J. L. Palmer -- Postoperative delirium indicating an adverse drug interaction involving the selective serotonin reuptake inhibitor, paroxetine? J Psychopharmacol, March 1, 2000; 14(2): 186 - 187. [PDF]